- 乳がん情報のブレストサービスTOP
- 医語よろしく
- Discrepancy between the subjective image held by cliniciansabout the treatment for node-negative HER2-positive breast cancer with smaller tumors and the recurrence rate calculated by adjuvant! Online. -Comparison to the image of treatment for triple-negative breast Cancer-
2011年1月～
【2011.7.1】
Discrepancy between the subjective image held by cliniciansabout the treatment for node-negative HER2-positive breast cancer with smaller tumors and the recurrence rate calculated by adjuvant! Online.
-Comparison to the image of treatment for triple-negative breast Cancer-
Discrepancy between the subjective image held by cliniciansabout the treatment for node-negative HER2-positive breast cancer with smaller tumors and the recurrence rate calculated by adjuvant! Online.
-Comparison to the image of treatment for triple-negative breast Cancer-
Interview with 32 clinicians demonstrated that nearly 50% of all clinicians considered adjuvant chemotherapy with trastuzumab to be unnecessary for patients with node-negative HER2-positive breast cancer with tumors smaller than or equal to 1 cm diameter(T≦1cm), while about 90% of clinicians indicated adequate adjuvant chemotherapy necessary for patients with node-positive triple-negative breast cancer(T≦1cm),
When 10-year recurrence rate was calculated for each group using Adjuvant! Online, the recurrence rate did not significantly differ between the groups (23% and 24% respectively). Therefore, the subjective image held by clinicians about the treatment of breast cancer was highly discrepant from the objective risk of tumor recurrence.
Clinicians should pay close attention to the fact that the risk for recurrence is not low for patients with node-negative HER2-positive breast cancer(T≦1cm). Adjuvant chemotherapy with trastuzumab is thus essential in such cases.
Key words : HER2-positive, Node negative, Trastuzumab
Jpn J Breast Cancer 26(2) : 207~213, 2011
Miyauchi M*1, Kawakami Y*2, Hashimoto H*3 and Nakamura R*4 (*1Breast Service Co., Ltd.,*2Kawakami Breast-thyroid Clinic,*3Chiba Foundation for Health Promotion Disease Prevention,*4division of Brest surgery, Chiba Cancer center)
